Can Fite BioPharma Ltd (CANF)

[midastouch017]

Can-Fite to Participate in Two BioPharma Partnering Conferences

Business Wire Business Wire•September 22, 2020

Can-Fite to Participate in Two BioPharma Partnering Conferences
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced the Company’s VP of Business Development, Dr. Sari Fishman, is participating in two conferences where she will conduct one-on-one meetings with pharmaceutical companies for potential distribution and partnerships for the Company’s drug candidates, Piclidenoson and Namodenoson. Both conferences include scheduled virtual partner meetings for Can-Fite, live sessions, and virtual networking.

BioPharmAmerica™ Digital
September 21-24, 2020
BIO-Europe® Digital
October 26–29, 2020
Can-Fite recently announced achieving primary and secondary endpoints in its Phase II study of Namodenoson in NASH. Interim top-line results are expected before the end of 2020 in two Phase III studies of Piclidenoson in rheumatoid arthritis and psoriasis. Additional trials are ongoing or expected to start in COVID-19 and liver cancer. Can-Fite has received approximately $18 million in upfront and milestone payments to date through licensing and distribution deals for its drug candidates.

https://finance.yahoo.com/news/fite-participate-two-biopharma-partnering-110000612.html